Introducing Rubraca
Loading Map....
You are invited to attend a Presentation and Dinner – Introducing Rubraca
Presented by: John Chan MD
Rubraca™ is indicated as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies. Select patients for therapy based on an FDA-approved companion diagnostic for Rubraca.